INVO Fertility announced its second quarter 2025 financial results, highlighting key metrics and achievements.
Revenue reached $1,863,654, marking a 1% increase from the previous quarter and setting a new record for the Company.
Operational highlights include recognition on Newsweek's List of America's Best Fertility Clinics and the launch of telehealth capabilities at the Wisconsin clinic.
Revenue Growth
Revenue increased by 1% compared to the previous quarter, reaching $1,863,654.
Recognition on Newsweek's List
The Wisconsin Fertility Institute was recognized on Newsweek's List of America's Best Fertility Clinics for 2025.
Innovative Services Expansion
INVO Fertility expanded its services by adding Platelet-Rich Plasma (PRP) therapy to the Wisconsin clinic's offerings.
New Patent Allowance
The Company received a notice of allowance for a new patent extending intellectual property protection on the INVOcell device.
Divestiture Completion
The Company completed the divestiture of NAYA Therapeutics, Inc., returning focus to fertility operations.
- INVO Fertility's revenue growth signals a positive trajectory, with a focus on expanding access to advanced fertility treatment.
- The recognition on Newsweek's List and the introduction of innovative services highlight the Company's commitment to excellence and patient-centered care.
INVO Fertility's strategic decisions, operational advancements, and growth indicate a promising future in the fertility healthcare sector.